The impact of omalizumab treatment in UK clinical practice for asthma

Not Applicable

Completed

• Conditions: Severe allergic asthma (consistent with the licence for omalizumab).; Respiratory; Asthma

• Registration Number: ISRCTN55772104
• Lead Sponsor: ovartis Pharmaceuticals (UK)

Brief Summary

2013 results in https://www.ncbi.nlm.nih.gov/pubmed/23574000

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-05-10
• Study Completion: 2013-08-01
• Last Update Posted: 26 February 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Patient to receive at least one dose of omalizumab for the treatment of severe persistent allergic asthma as part of normal clinical care
2. Patient aged 16 or over at initiation of omalizumab

Exclusion Criteria

1. Complete patient medical record for the 12 months pre-initiation of omalizumab is not available for review
2. Medical record contains insufficient data to complete the baseline study dataset (for patients recruited to the study after omalizumab initiation)
3. Patient declines to consent to research access to the medical record and/or researcher contact with the GP to obtain a complete study dataset
4. Previous bronchial thermoplasty
5. Previous omalizumab use
6. Current participation in any interventional trial of asthma treatment

Study & Design

• Study Type: Observational
• Study Design: Not specified